Clopidogrel, CYP2C19, and a black box

Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2013, Pages 241-248

  Ford, Neville F ^a,b   Taubert, Dirk ^c  

^a Woodfield Clinical Consulting LLC   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Clopidogrel; CYP2C19; CYP3A; Drug drug interactions; Lansoprazole; MACE; Omeprazole; Pharmacogenomics; Platelets; PPIs; Supersomes and hepatosomes

Indexed keywords

2 OXOCLOPIDOGREL; 5 HYDROXYOMEPRAZOLE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG METABOLITE; ERYTHROMYCIN; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RIFAMPICIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; BLACK BOX WARNING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DOSE COMPARISON; DRUG HYDROLYSIS; DRUG LABELING; DRUG METABOLISM; DRUG OXIDATION; DRUG SAFETY; EX VIVO STUDY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEMATOLOGY TEST KIT; HETEROZYGOTE; HUMAN; HYPOTHESIS; IN VITRO STUDY; LIVER MICROSOME METABOLISM; LOADING DRUG DOSE; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG LABELING; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84877869340     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.17     Document Type: Review

References (59)

1. O'Connor RE, Brady W, Brooks SC, et al. Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl. 3):S787-S817.
2. Blume H, Donath F, Warnke A, Schug B. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29 (9):769-784.
3. Li X, Andersson T, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazoleon human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827.
4. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74.
5. Takahashi M, Pang H, Kawabata K, Farid N, Kurihara A. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2008;48 (4):1219-1224.
6. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126-142.
7. Savi P, Pereillo JM, Uzabiaga MF, et al. Indentification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84(5):891-896.
8. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P-450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31(1):53-59.
9. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38(1):92-99.
10. Pereillo JM, Maftouh M, Andrieu A, et al. Srtucture and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30(11):1288- 1295.
11. Mansuy D, Dansette PM. Sulfenic acids as reactive intermediates in xenobiotic metabolism. Arch Biochem Biophys. 2011;507(1):174-185.
12. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17 (1):110-116.
13. McGinnity DF, Waters NJ, Tucker J, Riley RJ. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metab Dispos. 2008;36(6):1126-1134.
14. Van LM, Sarda S, Hargreaves JA, Rostami-Hodjegan A. Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism. J Pharm Sci. 2009;98(2):763-771.
15. Tuffal G, Roy S, Lavisse M, et al. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost. 2011;105(4):696-705.
16. Perla-Kajan J, Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 2009;24(3):931-936.
17. Reny JL, Combescure C, Daali Y, Fontana P. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and metaanalysis. J Thromb Haemost. 2012;10(7):1242-1251.
18. Taubert D, Bouman HJ, Van Werkum JW. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(21):2249-2250.
19. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel, risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32(13):1605-1613.
20. Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther. 2011;90(4):568-574.
21. Gong IY, Crown N, Suen CM, et al. Clarifying the importance of CYP2C19, PON1 in the mechanism of clopidogrel bioactivation, in vivo antiplatelet response. Eur Heart J. 2012;33:2856-2864.
22. Kurihara AHK, Kazui M, Ozeki T, Farid NA, Ikeda T. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for the two oxidation steps involved in the active metabolite formation. Drug Metab Rev. 2005;17(Suppl. 2):99.
23. Abell LM, Liu EC. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro. J Pharmacol Exp Ther. 2011;339(2):589-596.
24. Zahno A, Brecht K, Bodmer M, Bur D, Tsakiris DA, Krahenbuhl S. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol. 2010;161(2): 393-404.
25. Dansette PM, Rosi J, Bertho G, Mansuy D. Paraoxonase-1 and clopidogrel efficacy. Nat Med. 2011;17(9):1040-1041; author reply 2-4.
26. Bouman HJ, Schömig E, van Werkum JW, et al. Reply to: "Paraoxonase-1 and clopidogrel efficacy". Nat Med. 2011;17 (9):1042-1044.
27. Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol. 2012;25(2):348-356.
28. Camps J, Joven J, Mackness B, et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med. 2011;17(9):1041-1042; author reply 2-4.
29. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509.
30. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256-260.
31. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109(2):166-171.
32. Lau WC WT, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John's wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients. J Cardivascular Pharmacol. 2011;57(1):86-93.
33. Arant CB, Wessel TR, Olson MB, et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. J Am Coll Cardiol. 2004;43(11):2009-2014.
34. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndromes. JAMA. 2009;301 (9):937-944.
35. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors, clopidogrel. CMAJ. 2009;180(7):713-718.
36. Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754-762.
37. Aradi D, Magyarlaki T, Tokes-Fuzesi M, et al. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. Platelets. 2010;21(7):563-570.
38. Mega JL, Hochholzer W, Frelinger AI, et al. Dosing clopidogrel based on CYP2C19 genotype, the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306 (20):2221-2228.
39. Mega JL, Simon T, Collet J-P, et al. Reduced-function CYP2C19 genotype, risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA. 2010;304 (16):1821-1830.
40. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-offunction polymorphism, stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30(8):916-922.
41. Collet J-P, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphisms in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373 (January 24): 309-317.
42. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-1934.
43. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J. 2011;75(1):99-105.
44. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous intervention. J Am Coll Cardiol. 2011;58(19):1945-1954.
45. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in ontreatment platelet reactivity explained by CYP2C19*2genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart. 2011;97(15):1239-1244.
46. Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping versus genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI studt. J Thromb Haemost. 2012;10 (4):529-542.
47. Bhatt DL, Cryer, BL Contant CF. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363 (20):1909-1917.
48. Southworth MR, Temple R. Interaction of clopidogrel and omeprazole. N Engl J Med. 2010;363(20):1977.
49. Schmidt M, Johansen MB, Robertson DJ, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther. 2012. 35:165-174.
50. Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624-2641.
51. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343: d4588. doi: 10.1136/bmj.d4588
52. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2012. doi: 10.1016/j.ijcard2012.03. 085
53. Holmes MV, Perel P, Shah T, Hingorani AD, Casa JP. CYP2C19 genotype, clopidogrel metabolism platelet function and cardiovascular events. JAMA. 2011;306(24):2704-2714.
54. Douglas IJ, Evans SJW, Hingorani AD, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. 2012;345:e4388. doi: 10.1136/bmj.e4388
55. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474-482.
56. Johnson JA, Roden DM, Lesko LJ, et al. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther. 2012; 91(5):774-776.
57. Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun. 2005;327(4):1052-1057.
58. Fer M, Dreano Y, Lucas D, et al. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys. 2008;471(2):116-125.
59. Ford NF. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol. 2009;49(5):506-512.